Ishan [for Greg]'s questions to Pacira Biosciences Inc (PCRX) leadership • Q1 2025
Question
An analyst, Ishan, asked for color on the proportion of patients covered by Medicare under the NOPAIN Act across different surgical segments and inquired about the clinical data physicians and patients would need to see for wide adoption of a therapy like PCRX-201.
Answer
Chief Commercial Officer Brendan Teehan explained that the payer mix varies by setting, with more commercial coverage inpatient and in ASCs, while hospital outpatient settings skew more toward Medicare. CEO Frank Lee stated that for PCRX-201, providing a year or more of benefit is considered transformative by clinicians, noting the company has already shared encouraging two-year data and will present three-year data later in the year.